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INTRODUCTION:
Hemophilia is a congenital X-linked bleeding disorder that results from a deficiency of one of two
coagulation factors. The majority of individuals with hemophilia are deficient in factor VIII (FVIII), known as
hemophilia A. A smaller subset is deficient in factor IX (FIX), known as hemophilia B. Hemophilia A affects
1 in 5,000 male births, whereas hemophilia B affects 1 in 30,000 male births.1 There is wide variation in
disease severity amongst individuals with hemophilia. Approximately 60% are affected by the severe form,
defined as factor levels of less than 1%. Another 15% are affected by the moderate form (factor levels of 15%), and the remaining 25% are affected by the mild form (factor levels of 6-30%).2 Individuals with milder
forms of hemophilia may only experience significant bleeding episodes following an injury or other external
stimuli. Individuals with more severe forms experience spontaneous bleeding episodes, often into their joint
spaces, known as hemarthrosis.2 Hemarthrosis can progress to debilitating arthropathies, most commonly
in the ankles, knees, and elbows.3 However, bleeding does not only affect the joint spaces. Bleeding can
occur in any tissue or organ, and although musculoskeletal bleeding is characteristic of hemophilia,
epistaxis and bleeding of the mucus membranes is also common.4
BACKGROUND:
Although evidence of hemophilia exists in writings dating back to the second century AD, the first
modern description is credited to American physician Dr. John Conrad Otto in 1803. Otto wrote of an
inheritable bleeding disorder in which males were affected and transmission occurred via unaffected
females.5 For over one hundred years following Otto’s description, the disorder continued to be studied by
physicians all over the world. Many different theories regarding the pathophysiology of hemophilia were
proposed and subsequently disproven. The year 1937 marked a turning point in our understanding of
hemophilia. In 1937, Harvard physicians Arthur J. Patek and F.H.L. Taylor discovered that they could
temporarily shorten coagulation times in patients with hemophilia by adding a substance extracted from
plasma that they eventually called “anti-hemophilic globulin”.1, 2 In 1944, Alfredo Pavlovsky, a doctor in
Buenos Aires, discovered that the blood from one individual with hemophilia could temporarily correct the
coagulation defect of another individual with hemophilia. He had unintentionally stumbled upon two patients
with different deficiencies, one with a FVIII deficiency, and the other with a FIX deficiency1. These
deficiencies were later termed hemophilia A and hemophilia B, respectively. The culmination of these
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discoveries, among others, led to our current pathophysiologic understanding of hemophilia and set the
stage for research that would lead to hemophilia treatments.
Prior to the 1950s, the only treatment available for bleeding episodes in patients with hemophilia
was whole blood transfusion. It wasn’t until the late 1950s that hospitals and treatment centers began
transfusing fresh frozen plasma. However, these products did not contain enough FVIII or FIX to stop
severe bleeding, and most individuals with hemophilia died of internal hemorrhage in childhood or early
adulthood.1 By the end of 1960, the life expectancy for individuals with severe hemophilia was less than 20
years.2 In 1965, Judith Graham Pool, a researcher at Stanford University, discovered that when bags of
fresh frozen plasma were thawed slowly, an insoluble cryoprecipitate settled out of the solution.1,5,6 This
cryoprecipitate was subsequently found to contain the majority of the fibrinogen, factor VIII, factor XIII, von
Willebrand factor (vWF), and fibronectin that was originally dispersed within the fresh frozen plasma.7 This
discovery revolutionized hemophilia treatment as it allowed for adequate amounts of factor to be infused in
much smaller volumes. This led to an improved ability to control severe bleeding and made surgery a
possibility for patients with hemophilia.1 Not long after Pool’s discovery, scientists began to isolate factor
from cryoprecipitate using various fractionation and purification techniques. By 1970, freeze dried factor
concentrates were made available for individuals with hemophilia, allowing them to self-infuse their factor
products in the comfort of their own homes.3,6
Initially, the ability to mass-produce and infuse concentrated factor products offered individuals with
hemophilia the promise of longer, higher quality lives. However, in the early 1980s, approximately ten years
after the release of concentrated factor products, a frightening truth was brought to light. Due to nearly nonexistent donor screening protocols and the pooling of plasma from thousands of donors, 60-70% of
individuals that received factor products contracted the HIV virus. Furthermore, nearly 100% of them
contracted the hepatitis C virus.1 Thousands of patients died due to the complications of receiving
contaminated factor products.6 These products, which originally offered hope to so many individuals,
destroyed lives, tore apart families, and sparked numerous controversies across the globe. In response to
this horrific tragedy, donor screening protocols and viral inactivation techniques were developed.1,5 In 1981,
Haemate® P, the first pasteurized concentrate of FVIII/vWF, was introduced in Germany. The
pasteurization method used in the manufacturing process of Haemate® P successfully inactivated both the
HIV virus and the hepatitis C virus. Following the development of Haemate® P, various other inactivation
techniques were successfully developed, including heat and solvent-detergent treatments. By the end of
the 1980s, all factor products were produced using the aforementioned techniques.5
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In addition to the development of inactivation techniques, the FVIII gene was successfully cloned
for the first time in 1984, eventually leading to the development and licensure of recombinant human FVIII
(rFVIII) in 1992.3 Five years later, recombinant human FIX (rFIX) also became widely available for use.2
These factor replacement products were not only completely safe from viral transmission, they also made
factor products more widely available. Though originally pioneered decades earlier, using factor products
for primary prophylaxis became much more of a common practice in the United States during the 1990s,
likely due in large part to the newly established safety and availability of these products.2,5 Today, primary
prophylaxis is the standard of care for severe hemophilia in the United States, as well as in the majority of
other developed countries. Primary prophylaxis largely prevents bleeding episodes and joint disease
related to hemarthrosis.
Though the medical community should never seek to forget the thousands of lives affected by
contaminated factor products, the issue of unsafe products is almost entirely ameliorated in the present
day. With this behind us, the focus has shifted to other issues currently affecting the hemophilia community.
Current concerns include increasing the availability of factor products in underdeveloped countries,
increasing the half-life of our current factor products, treating hemophilia patients with inhibitors, and finally,
finding a cure for hemophilia.3 I will focus largely on inhibitor development in severe hemophilia A, including
pathophysiology, proposed risk factors, and current available treatments.
METHODS:
In July of 2018, I spent seven days at a summer camp for children with hemophilia and other
chronic bleeding disorders. Not only did I have the opportunity to learn from many experts in the field, I was
also able to get a glimpse of the day to day management of hemophilia, as well as gain an understanding
of how this disease has the potential to impact quality of life. The camp check-in process at the beginning
of the week offered me my first glimpse into the daily lives of these patients. The campers arrived alongside
their parents, wearing medical alert bracelets and carrying large boxes or coolers filled with factor products
and/or other medications that they would undoubtedly need over the course of the week. One camper
arrived in a wheelchair due to a recent joint bleed. Some others were unable to make it entirely due to
recent severe bleeds or hospitalizations. Every morning, campers filed into the health center after breakfast
for their prophylactic therapy, a practice that for many occurs triweekly. I observed young children, some no
older than eight, learn self-infusion, a life-long skill that nearly all patients with severe hemophilia must
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acquire. I was taken aback by the comradery amongst the campers, as well as the encouragement and
mentorship they offered one another while learning self-infusion. However, despite regular prophylaxis,
bleeding remains a concern. Many campers spent a lot of time in the health center, be it for their third
nosebleed of the day, a hard fall from a game of capture the flag, or simply to rest and ice achy joints that
had been previously damaged by hemarthrosis. Some campers were restricted from participating in more
intense camp activities due to recent injuries or bleeds. Though at camp this may be a minor
inconvenience, back at home, it may result in missed days at school or work. Furthermore, bleeds may
result in significant arthropathies and permanent joint damage. It was humbling and inspiring to witness the
bravery and adaptability of so many young people with hemophilia, and it was a joy to see how
advancements in medicine have allowed these children to thrive at a level that was impossible in years
prior. However, bleeding remains a common occurrence in many with hemophilia, and though none of the
children at camp had inhibitors at the time (some had been successfully treated with ITI), one can imagine
how this would have complicated things further.
To build upon the information I gained during this experience, I turned to the literature to learn
more about the occurrence and treatment of inhibitors in severe hemophilia A. To find articles, I used the
following resources: PubMed, Academic Search Premier, DynaMed, the New England Journal of Medicine,
UpToDate, the National Hemophilia Foundation, and the European Association for Haemophilia and Allied
Disorders. I included the following search terms: hemophilia, history of hemophilia, hemophilia treatments,
hemophilia with inhibitors, neutralizing antibodies in hemophilia A, hemophilia A with inhibitors, severe
hemophilia A, severe hemophilia A with inhibitors, risk factors for inhibitor development, treatment of
inhibitors in hemophilia, recombinant factor eight products, plasma-derived factor eight products, factor
eight inhibitor bypassing agents, and emicizumab.
DISCUSSION:
Inhibitor Development:
Inhibitors are FVIII-specific IgG alloantibodies that develop as a result of an immune response
against infused FVIII. Once in the bloodstream, inhibitors bind to FVIII in such a way to disrupt the
formation of the FVIII-FIX complex, thus inhibiting thrombin generation and preventing proper coagulation.8
This complication renders FVIII replacement therapies ineffective and predisposes patients to an increased
risk of morbidity and mortality. Inhibitor development is not only the most problematic complication facing
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the world of hemophilia treatment today, it is also the most expensive.9 The annual cost of treating
hemophilia with inhibitors is more than three times greater than that of treating hemophilia without
inhibitors. According to Guh et al., in the United States, hemophilia with inhibitors costs approximately
$446,945 per patient annually, with some patients requiring more than $1,000,000 annually. Compare that
to cost of hemophilia without inhibitors, which was found to be approximately $124,700 per patient
annually.10,11
The immune response to infused FVIII involves both humoral and cell-mediated immunity. In short,
FVIII is engulfed by antigen presenting cells (APCs) and FVIII-specific antigens are then presented on the
major histocompatibility class II complexes (MHCII). The antigens are then detected by T-cell receptors on
CD4+ helper T-cells, leading to their activation and proliferation into FVIII-specific effector and memory T
cells. Simultaneously, the activated helper T-cells directly bind to B cells. This binding leads to further
activation of the T-cells, resulting in the release of specific cytokines that are involved in upregulating the
immune system and promoting B cell proliferation and differentiation into FVIII-specific effector and memory
B cells. Furthermore, this binding provokes the release of FVIII-specific antibodies.12 Specifically, these
FVIII-specific antibodies are IgG alloantibodies that typically bind to either the A2 or C2 domain of FVIII and
disrupt the formation of the FVIII-FIX complex, thus inhibiting thrombin generation.8 After the initial immune
response, the presence of FVIII specific memory T and memory B cells results in the hastening of
subsequent immune responses against FVIII, a process known as anamnesis.
Though individuals with severe hemophilia A are the most likely subset to develop an inhibitor, the
majority of these individuals are unaffected by this complication. Inhibitors develop in ~30% of patients with
severe hemophilia A. In these patients, the onset of inhibitor development typically occurs within the first 50
days of exposure to FVIII. Conversely, in patients with non-severe hemophilia A that are only exposed to
FVIII intermittently, the incidence of inhibitor development increases with each subsequent exposure, with
the incidence reaching >15% after >125 exposures.13 The reason that an immune response occurs in some
individuals as opposed to others is largely misunderstood. Countless studies have found that the
development of inhibitors is multifactorial, with both genetic (non-modifiable) and environmental
(modifiable) risk factors involved. Well established risk factors for inhibitor development include the severity
of hemophilia, intensity of early FVIII exposure, concurrent immune system activation/environmental
stressor (trauma, surgery, vaccination, infection, etc.), family history of inhibitors, and use of on-demand
therapy over prophylactic therapy.4,8 Perhaps the two most prominent risk factors for inhibitor development
include patient genetics and the type of FVIII product used.
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Hemophilia A, by definition, is a genetic disease involving mutation(s) of the factor VIII gene.
However, there is wide variation amongst individuals regarding the type(s) of mutations present.
Interestingly, one of the largest predictors of inhibitor development is the genetic profile of the patient.14
Overall, the presence of large insertions/deletions spanning more than one domain and nonsense
mutations of the light chain are associated with the highest risk of inhibitor development. Mutations of
intermediate risk include large insertion/deletions spanning a single domain, nonsense mutations of the
heavy chain, intron-22 inversion, and intron-1 inversions. Mutations with lesser risk of inhibitor development
include small insertions/deletions, missense mutations, and splice site mutations.12
Whether or not the use of recombinant FVIII products (rFVIII) as opposed to plasma-derived factor
VIII products (pFVIII) increases the chance of inhibitor development has been widely debated. Ex vivo
studies have demonstrated that von Willebrand factor (vWF), which is present in pFVIII but not in rFVIII,
does play a protective role against inhibitor development. The proposed mechanism being that vWF is
involved in the prevention of the endocytosis of FVIII by dendritic cells and the uptake of FVIII by antigen
presenting cells. Furthermore, vWF competes with a subset of inhibitors for binding sites on the C2 domain
of FVIII.3 Despite these ex vivo studies, multiple observational and retrospective studies have failed to find
an increased risk of inhibitor development with the use of rFVIII. Recently, a study intended to settle this
ongoing debate was designed. The Survey of Inhibitors in Plasma-Products Exposed Toddlers (SIPPET)
was the first randomized clinical trial that compared plasma-derived and recombinant factor products. The
SIPPET trial included patients with severe hemophilia A under the age of 6 that were previously untreated
with any FVIII products. The previously untreated patients (PUPs) were divided into two groups: 125
patients received pFVIII, and 126 patients received rFVIII. Both groups were then followed and monitored
for inhibitor development. Of the 125 patients in the pFVIII group, 26.8% developed inhibitors within fifty
days of exposure. Of the 126 patients in the rFVIII group, 44.5% developed inhibitors within fifty days of
exposure. The authors concluded that the rFVIII group had an 87% higher risk of inhibitor development
than the pFVIII group.15 Despite the authors’ conclusions, several factors must be taken into consideration.
First, the recombinant factor products used in this trial were all produced from hamster-cell cultures. This is
not representative of all of the current recombinant factor products available, such as those produced from
human embryonic kidney cells (HEK) or those with extended half-lives.15,16 Second, because the trial only
included PUPs with less than fifty days of exposure to FVIII, its results may not apply to those who have
already been exposed to FVIII for more than fifty days.16 Finally, despite the lower incidence of inhibitor
development in the pFVIII group, 26.8% of these patients still developed inhibitors, suggesting that other
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factors must be at play.
Current Treatment Options:
The most widely used tool for quantifying inhibitors is the Bethesda Assay. Using this tool, inhibitor
titers are measured in Bethesda Units (BU) per milliliter. One BU is defined as the amount of plasma
inhibitor per milliliter that results in 50% residual Factor VIII activity. Patients with titers of <5 BU are
considered to have low titer inhibitors, whereas patients with titers of >5 BU are considered to have high
titer inhibitors. Generally speaking, high titer inhibitors are increasingly difficult to treat.17
Immune tolerance induction (ITI) is considered the standard of care for hemophilia patients with
inhibitors. ITI involves frequent exposures to high dose FVIII over several months to years. This is done in
an effort to induce tolerance via the proposed mechanisms of T-cell overstimulation and exhaustion,
inhibition of FVIII specific B memory cells, and the formation of anti-idiotypic antibodies.17 If ITI is
successful, patients are able to resume the use of standard FVIII products, thus reducing costs and
decreasing morbidity and mortality. The success rate of ITI is approximately 59-86% in patients with severe
hemophilia A with an inhibitor.3 Much like vFW may play a role in preventing inhibitor development, it has
been suggested that it may also play a role in increasing the success rate of ITI. However, studies
investigating whether or not the use of pfVIII as opposed to rfVIII in ITI increases the likelihood of
successful eradication of the inhibitor are largely inconclusive at this time.1
For the subset of patients in which ITI is unsuccessful, the inhibitor remains, and alternative
treatments will likely be needed to achieve hemostasis. Congenital hemophilia patients can typically
achieve hemostasis when FVIII levels reach 10-15% of what is considered normal in healthy populations.
Though seemingly a small percentage, it is nearly impossible to achieve in patients with high alloantibody
titers (>5 BU).8 Thus, these patients may require bypassing agents, either as prophylaxis or on-demand
therapy. Two bypassing agents are available, both of which have similar efficacies overall. However,
patients respond to each agent on an individual basis, and therefore failure of one agent warrants trial of
another. Factor Eight Inhibitor Bypassing Agent (FEIBA) contains plasma-derived FII (prothrombin), FIX,
FX, & FVIIa. It works primarily as an activated prothrombin concentrate (aPCC) that negates the
requirement for FVIII in achieving hemostasis.8 However, FEIBA holds a potential risk for anamnesis of the
inhibitor due to trace amounts of FVIII that may still be present in this plasma-derived product. Furthermore,
FEIBA requires large infusion volumes.4,17 Another option is Recombinant Factor VIIa (rFVII)
(NovoSeven®). Activated FVII has the ability to directly activate platelet-bound FX, which itself is a
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hemostatic agent. Because it is a recombinant agent, rFVIIa does not pose any risk of anamnesis.
However, due to its short half-life, treatment with rFVIIa may require frequent infusions to achieve
hemostasis, sometimes up to every 2 hours.4 A disadvantage of both FEIBA and rFVIIa is the absence of
reliable biomarkers to correlate with therapeutic dosing or treatment efficacy. This poses a number of risks,
including the risk of thrombosis.17
The newest drug on the scene, emicizumab (HEMLIBRA®), was approved for use in late 2017.
Emicizumab is a recombinant, humanized bispecific monoclonal antibody. It functions by binding FIX and
factor X on a phospholipid membrane, therefore eliminating the need for the cofactor function of FVIII.
Because emicizumab and FVIII are structurally dissimilar, emicizumab is not neutralized by inhibitors or
acted on by physiologic regulatory proteins.4,18 The initial phase III study of emicizumab included patients
with inhibitors using bypassing agents for either primary prophylaxis or on-demand therapy. Following
weekly subcutaneous injections of emicizumab, the study demonstrated a 79% bleed reduction for patients
previously on bypassing agent prophylaxis, and an 87% bleed reduction for patients previously using
bypassing agents for on-demand therapy.18 Despite these efficacious results, there still exists some major
concerns regarding the drug. Due to its binding characteristics, any amount of emicizumab in the plasma,
even small nontherapeutic levels, will correct the activated partial thromboplastin time (aPTT). This renders
the aPTT an inaccurate monitoring tool. Furthermore, it renders all assays based upon the aPTT, such as
the Bethesda assay, inaccurate as well.4 Without accurate tools of measure, monitoring efficacy and
determining therapeutic dosing becomes increasingly difficult. Furthermore, four serious adverse events of
thrombosis have occurred with emicizumab use. These include 2 cases of microangiopathy, 1 case of
cavernous sinus thrombosis, and 1 case of skin necrosis-superficial thrombophlebitis. However, all of these
events occurred when emicizumab was used in combination with multiple infusions of aPCC. Both cases of
microangiopathy resolved after aPCC was stopped and neither required anticoagulation.18
CONCLUSION:
Reflecting on the history of hemophilia and the progression of hemophilia treatment, it is difficult to
imagine that only sixty years ago, whole blood transfusion was the only treatment available, and the life
expectancy of individuals with hemophilia was under twenty years. It is almost more difficult to believe that
just over forty years ago, the tragedy of contaminated blood products was brought to light, and that many of
the individuals that received those blood products are still affected today. Fortunately, the safety and
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efficacy of factor products in the present day has given individuals with the disease a life expectancy similar
to that of healthy unaffected individuals. Unfortunately, as hemophilia treatments have evolved, so too has
the disease. The development of inhibitors remains the most challenging and expensive complication in the
treatment of hemophilia today.
Moving forward, further research involving the prevention of inhibitor development is essential.
Though evidence suggests that plasma-derived products may be less immunogenic, there simply is not
enough availability of these products to treat all individuals with hemophilia. However, given the current
evidence, providers can take steps to identify high risk individuals, and tailor treatments accordingly.
Patients with high risk genetic defects and/or other multiple non-modifiable risk factors should be
considered candidates for plasma-derived products. In addition, the research surrounding pFVIII and rFVIII
products should be shared with patients and families, thus allowing them to make informed decisions.
For individuals with established inhibitors, immune tolerance induction should remain first line
management due to its high potential to eradicate the inhibitor completely, thus reducing costs and
improving morbidity and mortality. Furthermore, it allows for the preservation of the role of FVIII within the
body, which may do more than science has yet discovered.
Though immune tolerance induction is effective in the majority of inhibitor patients, it does not
eradicate all inhibitors. For that reason, research surrounding bypassing agents and novel agents such as
emicizumab must continue. Though current research has demonstrated high efficacy amongst these
products, they are expensive and not without safety concerns. Furthermore, there are no reliable
biomarkers by which to monitor and dose these medications.
Despite numerous recent advancements, medicine has not yet been able to achieve hemostasis
with the use of exogenous products in a completely safe and effective manner. Though we may never be
able to master the intricacies of this complex mechanism, given what is at stake, it is important that this
effort continues.
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